Aspira Women’s Health resumed with a Buy at Alliance Global Partners

Alliance Global Partners resumed coverage of Aspira Women’s Health with a Buy rating and $7.20 price target. The company is focused on transforming women’s gynecologic health through the development of non-invasive diagnostic tests for ovarian cancer and endometriosis, the analyst tells investors in a research note. The firm says a recent executive order also signed by President Biden to provide $12B in funding for women’s health research highlights the current unmet medical need present in the women’s health space. It believes Aspira’s OvaSuite covers current unmet medical need present in diagnosing ovarian cancer.